PMID- 32278343
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20200907
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Apr 11
TI  - A prospective cohort study of MTHFR C677T gene polymorphism and its influence on 
      the therapeutic effect of homocysteine in stroke patients with 
      hyperhomocysteinemia.
PG  - 128
LID - 10.1186/s12883-020-01701-8 [doi]
LID - 128
AB  - BACKGROUND: Hyperhomocysteinemia (HHCY) is a risk factor for cardiovascular and 
      cerebrovascular diseases. The C677T 5, 10-methylenetetrahydrofolate reductase 
      (MTHFR) gene polymorphism increases homocysteine (HCY) levels. This study 
      analyzed the relationship between C677T MTHFR polymorphism and the therapeutic 
      effect of lowering HCY in stroke patients with HHCY. METHODS: Baseline data were 
      collected from stroke patients with HHCY for this prospective cohort study. The 
      C677T MTHFR genotype was detected by polymerase chain reaction-restriction 
      fragment length polymorphism and the therapeutic effect to reduce HCY was 
      compared. RESULTS: Of 200 stroke patients 162 (81.0%) completed follow-up and 
      were evaluated. Most of them responded well to treatment (103 cases, 63.5%), but 
      59 (36.4%) patients were in the poor efficacy group. There was a significant 
      difference in terms of age (P < 0.001), hypertension (P = 0.041), hyperuricemia 
      (P = 0.042), HCY after treatment (P < 0.001), and MTHFR genotype (P < 0.001) 
      between the poor efficacy and effective groups, with increased frequency of the 
      TT genotype in the poor efficacy group. Logistic regression showed that the T 
      allele was associated with poor efficacy (OR = 0.733, 95%CI: 0.693, 0.862, 
      P < 0.001). In the codominant model the TT genotype was associated with poor 
      outcome (OR = 0.862, 95%CI: 0.767, 0.970, P = 0.017) and this was also the case 
      in the recessive model (OR = 0.585, 95%CI: 0.462, 0.741, P < 0.001) but there was 
      no association between CT and TT in the dominant model. CONCLUSIONS: The T allele 
      and TT genotype of the MTHFR C677T polymorphism was associated with poor HCY 
      reduction treatment efficacy in stroke patients with HHCY. TRIAL REGISTRATION: 
      The registration number of the clinical trial is ChiCTR1800020048. Registration 
      date: December 12, 2018.
FAU - Du, Xiaoxia
AU  - Du X
AD  - Department of Neurorehabilitation, School of Rehabilitation Medicine, Capital 
      Medical University, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, 
      Beijing, 100068, China. 364906784@qq.com.
FAU - Xiao, Lin
AU  - Xiao L
AD  - Department of Neurorehabilitation, School of Rehabilitation Medicine, Capital 
      Medical University, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, 
      Beijing, 100068, China.
FAU - Sun, Rong
AU  - Sun R
AD  - Department of Neurorehabilitation, School of Rehabilitation Medicine, Capital 
      Medical University, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, 
      Beijing, 100068, China.
FAU - Li, Kunpeng
AU  - Li K
AD  - Case Statistics Office, School of Rehabilitation Medicine, Capital Medical 
      University, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, 
      Beijing, 100068, China.
FAU - Liang, Lin
AU  - Liang L
AD  - Department of Clinical Laboratory, School of Rehabilitation Medicine, Capital 
      Medical University, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, 
      Beijing, 100068, China.
FAU - Song, Luping
AU  - Song L
AD  - Department of Neurorehabilitation, School of Rehabilitation Medicine, Capital 
      Medical University, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, 
      Beijing, 100068, China.
FAU - Liu, Zhizhong
AU  - Liu Z
AD  - Department of Clinical Laboratory, School of Rehabilitation Medicine, Capital 
      Medical University, Beijing Bo'Ai Hospital, China Rehabilitation Research Center, 
      Beijing, 100068, China. lzzlab@126.com.
LA  - eng
GR  - 2015zx-21, 2016zx-15, 2018zx-3/Basic Scientific Research Foundation of China 
      Rehabilitation Research Center/
PT  - Journal Article
DEP - 20200411
PL  - England
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - EC 1.5.1.20 (MTHFR protein, human)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Cohort Studies
MH  - Female
MH  - Genotype
MH  - Homocysteine/*blood
MH  - Humans
MH  - Hyperhomocysteinemia/*therapy
MH  - Male
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
MH  - Middle Aged
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - Polymorphism, Restriction Fragment Length
MH  - Prospective Studies
MH  - Risk Factors
MH  - Stroke/*complications
PMC - PMC7149884
OTO - NOTNLM
OT  - Homocysteine
OT  - Intracerebral hemorrhage
OT  - Methylenetetrahydrofolate reductase
OT  - Single nucleotide polymorphism
OT  - Stroke
COIS- The authors declare no conflicts of interest.
EDAT- 2020/04/13 06:00
MHDA- 2020/09/08 06:00
PMCR- 2020/04/11
CRDT- 2020/04/13 06:00
PHST- 2019/05/05 00:00 [received]
PHST- 2020/03/26 00:00 [accepted]
PHST- 2020/04/13 06:00 [entrez]
PHST- 2020/04/13 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2020/04/11 00:00 [pmc-release]
AID - 10.1186/s12883-020-01701-8 [pii]
AID - 1701 [pii]
AID - 10.1186/s12883-020-01701-8 [doi]
PST - epublish
SO  - BMC Neurol. 2020 Apr 11;20(1):128. doi: 10.1186/s12883-020-01701-8.